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ISOPHOSPHAMIDE (IP) is a new anti-
neoplastic drug, chemically related to
cyclophosphamide (CP) by transposition
of a chloroethyl group from the exocyclic
to endocyclicnitrogen. Recently, extensive
clinical investigations (Cohen & Mittleman
1973, Creaven et al., 1976) have praised the
lower toxicity of IP than of CP. Further-
more, previous experimental data are very
encouraging. They demonstrate that the
antitumour effect of IP is similar to, or
higher tha,n, that of CP when assayed on
some experimental tumours of the rat,
such as DS-carcinosarcoma (Von Ardenne
et al., 1971) Yoshida sarcoma (Brock,
1972) and Jensen sarcoma (Van Dyk et al.,
1972).
Therefore, in order to verify this differ-
ence and to estimate the relative efficacy
of the 2 alkylating agents, we have
compared the toxicity (expressed as LD50)
andthe therapeutic effectiveness ofCP and
IP on Lewis lung carcinoma (3LL) after a
single dose 5 days after tumour implanta-
tion.
Our experimental model was implanted
i.m. in C57BL mice with 5 x 105 viable
tumour cells. The tumour was aseptically
removed from the leg and made into a
cell suspension as previously described
(DeWys, 1972). Tumour growth was
calculated by caliper measurement of
diameters, and the Wexler procedure was
used for metastasis counting (Wexler,
1966). CP and IP, dissolved in double-
distilled water, were injected i.p. in a
volume of 0-01 ml/g body weight.
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The toxicity expressed as LD50 has
been 360 mg/kg for CP and 540 mg/kg
for IP, which agrees with the literature.
The following quantitative endpoints
were used to assess antitumour effective-
ness of the drugs;
(i) tumour growth inhibition (T/C) ob-
tained by caliper measurements as
described above, and
(ii) tumour growth delay in days (T-C)
to a predetermined size (ig).
As shown in the Table, both CP and IP
revealed a dose-dependent chemothera-
peutic activity when administered in
single doses to 3LL-bearing mice.
In particular, after CP and IP given i.p.,
the i.m. implanted 3LL exhibits a very
remarkable inhibition of the primary
tumour growth at increasing doses up to
a "cure") after 300 mg/kg CP and 500
mg/kg IP.
Response of 3LL to CP and IP was also
evaluated by the time required for the
treated tumours to reach the size of 1g.
Data reported in the Table show the
growth delay of the tumours after chemo-
therapy relative to tumours in the control
group. As can be seen, although tumour-
growth retardation was shown by tumour-
bearing mice afterboth CP or IP (at all con-
centrations tested) a greater effect of CP
than IP at the same active dose was
found. In particular, after 300 mg/kg CP,
tumour growth was arrested, and mice
showed a complete disease-free survival
over 90 days, being considered "cured".632 A. CORSI, F. CALABRESI AND C. GRECO
TABLE.-Effect of stngle cyclophosphamide and isophosphamide doses on Lewis
lung carcinoma
Treatment* Effect on primary Tumour
---- ,- -Effect on Tumour-free
Dose Average wt.t T- C Metastases survivors at
Drug (mg/kg) (g±s.e.) T/Ct (days) T/Ct %ILS 90 days (%)
Control 5 -23i0 72 0
CP 100 4-11±0-71 0-78 4 0-84 22-5 0
200 0-50±0-21 0 09 16 0-62 68-5 33
300 § § § 0 >261-2 100
IP 100 5-83±0-70 1.11 0-6 0-64 10-8 0
200 2-31±0-47 0 44 9 05 0-65 29-8 0
300 0 46±0 40 0 08 17 0-66 110 20
400 0 0 25 0 52 128 60
500 § § § 0 >261-2 100
* Single doses were given 5 days after i.m. transplant of 5 x 105 viable tumour cells.
t Tumour weights at the median day of control death (25 day).
I Ratio between the average values of each treated group and the relevant control.
§ Treated tumours remain below the limit of palpation for 90 days.
An equal dose of IP arrested the tumour
growth for a remarkably long period
(17 days) but it was not "curative". A
complete disease-free survival was ob-
tained only after a 500 mg/kg IP
treatment.
In further experiments, the effect of
CP and IP on lung metastases was inves-
tigated. As illustrated in the Table,
single doses of CP and IP 5 days after
tumour implantation induced a significant
reduction in the number of lung nodules.
Again, a total disappearance of metas-
tases was found only after a dose of IP
1*6 times that of CP.
The purpose of this research was to
verify preliminarily the therapeutic and
toxic effects of IP vs its analogue, CP on
3LL tumour. This experimental model has
been chosen both because of its well-
known response to CP and of the simil-
arity of its particular metastasizing be-
haviour to that of human tumours.
Preliminary clinical investigations seem-
ed to demonstrate that IP exhibited a less
toxic effect than CP, maintaining, on the
other hand, a similar therapeutic
effectiveness.
Our preliminary results reported here
do not support a real advantage of IP
over CP in their respective balances
between toxic and therapeutic effects. In
fact, LD50 IP/LD50 CP = 1-5 but the
dose of IP necessary to reach the same
"curative" effect on 3LL tumour is 1-6
times that of CP.
Because of the clinical interest of these
experimental data, we are performing
further studies on 3LL, using different
schedules, including those for adjuvant
therapy after surgery, in order to draw
more general conclusions on the claimed
advantage of this derivative of CP.
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